About The Study: A total of nearly 137 million adults, representing more than half of all U.S. adults, are eligible for semaglutide therapy. This exceeds the number of adults eligible for statins (approximately 82 million), currently the most prescribed pharmaceuticals among U.S. adults.
Corresponding Author: To contact the corresponding author, Dhruv S. Kazi, MD, MS, email dkazi@bidmc.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.4657)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Heart Association’s Scientific Sessions 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4657?guestAccessKey=baa342ec-8c33-4211-98eb-b1ec08d802eb&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824
JAMA Cardiology